Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen

Rare diseases: drug re-discovery Canadian researchers use three different approaches to identify drugs that could be repurposed to treat rare genetic diseases. Prompted by the growing gap between known rare diseases and therapies and postulating that diseases might be treated with drugs that modulat...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: A. J. Mears, S. C. Schock, J. Hadwen, S. Putos, D. Dyment, K. M. Boycott, Alex MacKenzie
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
R
Acceso en línea:https://doaj.org/article/3d2784f19fee4e1ebd89fab035bb9d11
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:3d2784f19fee4e1ebd89fab035bb9d11
record_format dspace
spelling oai:doaj.org-article:3d2784f19fee4e1ebd89fab035bb9d112021-12-02T12:34:18ZMining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen10.1038/s41525-017-0018-32056-7944https://doaj.org/article/3d2784f19fee4e1ebd89fab035bb9d112017-04-01T00:00:00Zhttps://doi.org/10.1038/s41525-017-0018-3https://doaj.org/toc/2056-7944Rare diseases: drug re-discovery Canadian researchers use three different approaches to identify drugs that could be repurposed to treat rare genetic diseases. Prompted by the growing gap between known rare diseases and therapies and postulating that diseases might be treated with drugs that modulate levels of disease-related proteins, Alex Mackenzie at the University of Ottawa and colleagues, studied the impact of 300 clinically approved drugs on 75 rare disease associated genes. Analyses of Connectivity Map gene expression data, published texts and a cell-based screening assay revealed thousands of putative and potentially clinically beneficial interactions. Although just 5–10% altered protein expression, the different approaches were complementary rather than redundant methodologies identifying potentially useful starting points on the path to rare disease therapy.A. J. MearsS. C. SchockJ. HadwenS. PutosD. DymentK. M. BoycottAlex MacKenzieNature PortfolioarticleMedicineRGeneticsQH426-470ENnpj Genomic Medicine, Vol 2, Iss 1, Pp 1-8 (2017)
institution DOAJ
collection DOAJ
language EN
topic Medicine
R
Genetics
QH426-470
spellingShingle Medicine
R
Genetics
QH426-470
A. J. Mears
S. C. Schock
J. Hadwen
S. Putos
D. Dyment
K. M. Boycott
Alex MacKenzie
Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen
description Rare diseases: drug re-discovery Canadian researchers use three different approaches to identify drugs that could be repurposed to treat rare genetic diseases. Prompted by the growing gap between known rare diseases and therapies and postulating that diseases might be treated with drugs that modulate levels of disease-related proteins, Alex Mackenzie at the University of Ottawa and colleagues, studied the impact of 300 clinically approved drugs on 75 rare disease associated genes. Analyses of Connectivity Map gene expression data, published texts and a cell-based screening assay revealed thousands of putative and potentially clinically beneficial interactions. Although just 5–10% altered protein expression, the different approaches were complementary rather than redundant methodologies identifying potentially useful starting points on the path to rare disease therapy.
format article
author A. J. Mears
S. C. Schock
J. Hadwen
S. Putos
D. Dyment
K. M. Boycott
Alex MacKenzie
author_facet A. J. Mears
S. C. Schock
J. Hadwen
S. Putos
D. Dyment
K. M. Boycott
Alex MacKenzie
author_sort A. J. Mears
title Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen
title_short Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen
title_full Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen
title_fullStr Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen
title_full_unstemmed Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen
title_sort mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen
publisher Nature Portfolio
publishDate 2017
url https://doaj.org/article/3d2784f19fee4e1ebd89fab035bb9d11
work_keys_str_mv AT ajmears miningthetranscriptomeforrarediseasetherapiesacomparisonoftheefficienciesoftwodataminingapproachesandatargetedcellbaseddrugscreen
AT scschock miningthetranscriptomeforrarediseasetherapiesacomparisonoftheefficienciesoftwodataminingapproachesandatargetedcellbaseddrugscreen
AT jhadwen miningthetranscriptomeforrarediseasetherapiesacomparisonoftheefficienciesoftwodataminingapproachesandatargetedcellbaseddrugscreen
AT sputos miningthetranscriptomeforrarediseasetherapiesacomparisonoftheefficienciesoftwodataminingapproachesandatargetedcellbaseddrugscreen
AT ddyment miningthetranscriptomeforrarediseasetherapiesacomparisonoftheefficienciesoftwodataminingapproachesandatargetedcellbaseddrugscreen
AT kmboycott miningthetranscriptomeforrarediseasetherapiesacomparisonoftheefficienciesoftwodataminingapproachesandatargetedcellbaseddrugscreen
AT alexmackenzie miningthetranscriptomeforrarediseasetherapiesacomparisonoftheefficienciesoftwodataminingapproachesandatargetedcellbaseddrugscreen
_version_ 1718393853553147904